Skip to main content

Clinical trial investigates ‘Light Touch’ approach to wet AMD treatment 

September 25, 2025

News from our full member Moorfields Eye Hospital

 A clinical trial led by NIHR Moorfields Clinical Research Facility will explore a new ‘light-touch’ treatment approach for patients with neovascular age-related macular degeneration (wet AMD) that could result in fewer injections and reduced number of clinic visits. 

Funded by Roche, the trial will compare two treatment strategies for patients who have been receiving regular intravitreal injections and are eligible to switch to faricimab (VABYSMO®, Hoffmann-La Roche), an anti-angiogenic agent that patients are increasingly being switched to in order to stem the leaking of retinal blood vessels causing vision loss. 

The first strategy, currently used for patients switching over to faricimab, is an initial course of three, monthly intravitreal injections followed by a personalised schedule of injections tailored for the patient according to the level of disease progression. 

The second, light touch regimen is a single initial injection at the time of switching over, followed immediately by a personalised schedule of injections. 

A phase III clinical trial spanning more than 12 centres, the Light Touch study will assess whether the more streamlined treatment approach is as clinically effective as the traditional three-month induction phase. A positive outcome could lead to a more patient-friendly protocol, maintaining visual outcomes while reducing the burden of frequent injections. 

Over the course of two years, 230 patients aged 50 and older with wet AMD will be assessed for the efficacy of the two treatment options. The study will randomize participants into two arms: a standard care group receiving three initial monthly injections and an intervention group receiving a single initial injection with treatment intervals based on their pre-switch treatment schedule. 

“This clinical trial represents a significant opportunity to transform how we manage neovascular age-related macular degeneration,” said Dr. Dun Jack Fu, principal investigator at NIHR Moorfields Clinical Research Facility. “By exploring a potentially less intensive treatment approach, we hope to improve patient experience without compromising vision outcomes,” added fellow investigator Dr Livia Faes. 

Faricimab, already approved by EMA, MHRA, and NICE for wet AMD treatment, will be used in both study arms. The research will comprehensively evaluate visual acuity improvements, vision loss prevention, anatomical changes, and patient-reported outcomes. 

Compared with other licensed agents, which target only one pathway — vascular endothelial growth factor (VEGF) — faricimab takes a dual approach, targeting both the VEGF and angiopoietin-2 pathways, to inhibit leakage of blood vessels in the retina. Farcimab has been found to control disease activity with fewer injections, and longer time intervals between injections. The Light Touch trial seeks to investigate whether even longer time intervals will be clinically effective. 

Date: 25 September 2025
Source: Moorfields

Older news


More recent

£12.2m health technology hub puts the North East at the forefront of disease prevention

News from our full member South Tyneside and Sunderland NHS Foundation Trust A landmark £9.1 million investment from the UK government through UK Research and Innovation (UKRI), alongside a further £3.1 million from partners, will establish a major new health technology hub.It brings together universities, the NHS, and industry, putting the north-east at the forefront […]

New WAEH Full Member introduction: Medical College of Wisconsin Eye Institute

The Froedtert & the Medical College of Wisconsin Eye Institute is a community of clinicians, scientists, educators and staff working together to preserve, protect and restore sight. For 50 years, the Eye Institute has built its work on a simple idea that the best care and discoveries happen when people learn from one another. The […]

WAEH welcomes two new full members

We are delighted to announce that two new institutions have officially joined the World Association of Eye Hospitals (WAEH) as Full Members today, further strengthening our global network of leading eye care institutions. Altino Ventura Foundation (FAV) – Recife, Brazil Based in Recife, northeastern Brazil, the Altino Ventura Foundation is a non-profit institution dedicated to […]

280 Lawmakers and Legislative Staff Screened in Monrovia: Free Eye Screening at the Capitol Building

News from our full member LV Prasad Eye Institute The LVPEI–Liberia Eye Center, operating at the John F. Kennedy Memorial Medical Center (JFKMC), held a free eye-screening program at the Capitol Building in Monrovia as part of the World Sight Day 2026 observance. The program offered eye-screening services to members of the House of Representatives […]

LVPEI Monthly Note: Forty Years

News from our full member LV Prasad Eye Institute On the 17th of this month, we celebrated the 40th anniversary of our founding. Forty years is a remarkable milestone for any organisation. For LVPEI, this day marked the culmination of a series of extraordinary decisions made four decades ago. The Raos gave up a thriving […]